Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fevipiprant add-on therapy in uncontrolled severe eosinophilic asthma
2015-003172-67Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing Fevipiprant add-on to standard of care with Placebo add-on to standard of care (2 arms). Primary endpoint: Rate of moderate-to-severe asthma exacerbations. Started Oct 2015; status: completed.
02
Drugs
fevipiprant
03
Conditions
asthma
Beyond the preview
Go deeper on 2015-003172-67.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003172-67.